focus -WSS

focus

author：explore 2025-09-06 03:17:30 - browse：595

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

WSS

Mayo Clinic plans $5B tech

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

30 years of 'Listening to Prozac'

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

FDA investigates CAR

China dismisses criticism of top diplomat's comments appearing to push for race

focus

focus

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Organ aging and disease risk measured by new blood test

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ReNAgade cuts staff seven months after raising $300 million

Supreme Court strikes down use of affirmative action

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Alkermes shareholders re

ReNAgade cuts staff seven months after raising $300 million

What does generative AI mean for health care? We asked experts

Princess Kate attends Wimbledon with Roger Federer: See the photos

hotspot

BIO selects John Crowley as new CEO

Fetal surgery at risk from Dobbs and new abortion restrictions

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Diagnostic tests are hitting their mathematical limits

What to do when lifesaving products contribute to climate change

2 million sign

Wikipedia

focus

focus

focus